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Objective: To assess the magnitude and severity of the 2012 influenza season in Victoria, Australia using surveillance data 
from five sources.
Methods: Data from influenza notifications, sentinel general practices, a sentinel hospital network, a sentinel locum service 
and strain typing databases for 2012 were descriptively analysed.
Results: Influenza and influenza-like illness activity was moderate compared to previous years, although a considerable 
increase in notified laboratory-confirmed influenza was observed. Type A influenza comprised between 83% and 87% 
of cases from the general practitioners, hospitals and notifiable surveillance data. Influenza A/H3 was dominant in 
July and August, and most tested isolates were antigenically similar to the A/Perth/16/2009 virus used in the vaccine. 
There was a smaller peak of influenza type B in September. No tested viruses were resistant to any neuraminidase inhibitor 
antivirals. Higher proportions of type A/H3, hospitalized cases and those with a comorbid condition indicated for influenza 
vaccination were aged 65 years or older. Influenza vaccination coverage among  influenza-like illness patients was 24% in 
sentinel general practices and 50% in hospitals.
Discussion: The 2012 influenza season in Victoria was average compared to previous years, with an increased dominance 
of A/H3 accompanied by increases in older and hospitalized cases. Differences in magnitude and the epidemiological 
profile of cases detected by the different data sources demonstrate the importance of using a range of surveillance data to 
assess the relative severity of influenza seasons.
Victoria is Australia’s southernmost mainland state with a population of approximately 5.5 million and a median age of 37.3 years.1 It has a temperate 
climate and an influenza season that usually occurs 
between May and October. The Victorian influenza 
surveillance system consists of several surveillance data 
sources used to monitor seasonal influenza and influenza-
like illness (ILI) activity in Victoria: notified laboratory-
confirmed influenza, sentinel general practices and 
hospitals, a sentinel metropolitan locum service and 
reference laboratory typing.
Medical practitioners and laboratory personnel are 
required by state law to notify the Department of Health 
of all laboratory-confirmed cases of influenza within 
five days of diagnosis. Identification, demographic and 
diagnostic data must also accompany the notification.
The Victorian General Practice Sentinel Surveillance 
(GPSS) programme provides reports on ILI by sentinel 
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general practitioners (GPs) from May to October each 
year. A subset of these ILI cases is swabbed for laboratory 
testing for influenza.2 The Influenza Complications 
Alert Network (FluCAN) is a real-time sentinel hospital 
surveillance system for acute respiratory disease and 
collects surveillance data on hospitalised adults with 
laboratory-confirmed influenza. 
The Melbourne Medical Deputising Service 
(MMDS) is the largest medical locum service in Australia 
and provides 24-hour medical services to patients at 
their residence in the Melbourne metropolitan area and 
Geelong. MMDS provides the proportion of ILI diagnoses 
made from all consultations.
Influenza-positive samples submitted to the 
World Health Organization (WHO) Collaborating Centre 
for Reference and Research on Influenza for strain 
characterization and antiviral drug sensitivity testing 
comprise the fifth surveillance data source.
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on swabbed patients included: age, sex, symptoms 
(fever, cough, fatigue, myalgia, other), seasonal influenza 
vaccination status (for 2012 and the previous 2011 
vaccines), date of vaccination/s and any co-morbidity for 
which influenza vaccination is recommended.4
Testing of these clinical specimens comprised 
extraction of ribonucleic acid and in-house validated 
real-time multiplex polymerase chain reaction (PCR) 
assays to detect type A influenza viruses (matrix gene), 
type B influenza viruses (nucleoprotein gene) and type C 
influenza viruses (matrix gene). Influenza A virus-positive 
samples were further subtyped using individual real-time 
PCR assays incorporating primers and probes specific for 
the haemagglutinin gene of A(H1N1)pdm09 and A(H3) 
strains.
Infl uenza Complications Alert Network
FluCAN is a hospital-based programme that collects 
surveillance data on hospitalized patients with laboratory-
confirmed influenza in near real-time.5 The network 
also aims to estimate vaccine coverage and vaccine 
effectiveness by comparing vaccination status in PCR-
confirmed cases with a sample of test-negative controls. 
In Victoria, four hospitals are involved, two of which 
have paediatric units that collect data on hospitalized 
children.6 Subtyping of influenza A virus infections is not 
routinely conducted in FluCAN.
Melbourne Medical Deputising Service
Weekly rates of influenza-related diagnoses by MMDS 
clinicians per 1000 consultations were calculated from 
records returned from the MMDS clinical database 
using the search terms “influenza” and “flu.” To avoid 
inclusion of those immunized prophylactically, records 
that contained the terms “Fluvax,” “at risk” and 
“immunization” were excluded.
Strain characterization and antiviral resistance 
testing
In 2012, all influenza-positive GPSS samples tested by 
the Victorian Infectious Diseases Reference Laboratory 
(VIDRL) as well as a selection of virus specimens and 
isolates tested by other Victorian laboratories were 
forwarded to the WHO Collaborating Centre for Reference 
and Research on Influenza for strain characterization 
and antiviral drug sensitivity testing. Samples were 
The objectives of the Victorian influenza surveillance 
system are to: monitor the epidemiology of laboratory-
confirmed influenza in Victoria; identify the onset, 
duration and relative severity of annual influenza seasons 
in Victoria; provide samples for the characterization of 
circulating influenza strains in the community to assist 
in the evaluation of the current seasonal vaccine and 
formulation of the following season’s vaccine; provide 
potential for early recognition of new influenza viruses 
and new or emerging respiratory diseases; and estimate 
influenza vaccine effectiveness each year.
Here we describe the epidemiology of the 2012 
influenza season from the Victorian influenza surveillance 
system.
METHODS
Notifi able diseases surveillance (notifi ed cases)
Records of all laboratory-confirmed influenza cases 
(defined as detection of influenza virus by nucleic acid 
testing or culture from an appropriate respiratory tract 
specimen) with a 2012 notification date were extracted 
from the Department of Health Public Health Event 
Surveillance System on 19 March 2013. For consistency 
and comparability only cases classified as “routinely 
notified” were used in the descriptive analyses; this 
excluded cases identified from outbreak investigations 
and GPSS but included FluCAN cases, which were 
unable to be separated from the data set. As this report 
focuses on case-based surveillance, notified institutional 
outbreaks were excluded.
General Practice Sentinel Surveillance 
programme
In 2012, 104 GPs (74 from 29 metropolitan practices 
and 30 from 12 rural practices) participated in 
GPSS, which operated from 30 April to 28 October 
(weeks 18 to 43) inclusive. The number of ILIs, defined 
as a case with fever, cough and fatigue/malaise,3 and 
total consultations per week were submitted weekly 
by fax, e-mail or online submission. ILI rates were 
calculated as the number of ILI patients per 1000 
consultations.
GPs collected either a nose or throat swab from a 
subset of patients presenting within four days of symptom 
onset, chosen at the discretion of the GP. Data collected 
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1000 consultations). ILI cases peaked at 14.9 and 
22.3 per 1000 consultations for the GPSS and MMDS 
systems during the week ending 15 July and one week 
later, respectively; both were slightly higher than those 
observed in 2010 and 2011 (Figure 1). Elevated ILI 
activity was sustained in MMDS for approximately 
two months beginning in early July (Figure 2).
Laboratory-confi rmed infl uenza
Laboratory-confirmed influenza cases were reported 
from three sources – notified cases (n = 5058), GPSS 
(n = 280) and FluCAN (n = 389) (Table 1). There 
was no clearly defined peak for notified cases in 2012, 
although 72% were notified in the two months between 
mid-July and mid-September (Figure 2). There were also 
no well-defined peaks for laboratory-confirmed cases of 
influenza from GPSS and FluCAN, although for FluCAN 
hospitals the highest number of cases admitted was in 
mid-to-late July (Figure 2).
Most notified cases (n = 4278; 85%) were 
influenza type A with subtyping reported for 223 (5%); of 
these, 67 (30%) were H1 and 156 (70%) were H3. H3 
cases were detected throughout the peak period while 
H1 cases were mainly reported in July. There were also 
745 cases (15%) of influenza type B notified, 
predominantly in the latter half of the surveillance period 
(Figure 3); 29 cases of type A and type B coinfection; 
and six cases of type C infections.
first inoculated into Madin-Darby Canine Kidney cells 
to obtain virus isolates. Those successfully isolated 
were then analysed by haemagglutination inhibition assay 
to determine antigenic similarity to the current vaccine 
strains. Isolates were also tested in a neuraminidase 
inhibition assay to determine susceptibility to the antiviral 
drugs oseltamivir, zanamivir, peramivir and laninamivir.
Data analyses
Descriptive analyses of the surveillance data were 
conducted in Microsoft Excel. Distributions of influenza 
and vaccination status by type/subtype, age group and 
presence of a comorbid condition were compared using 
the chi-squared test in Stata (version 10.0; StataCorp 
LP, College Station, TX, USA) with P < 0.05 considered 
significant.
RESULTS
Infl uenza-like illness
In 2012 GPPS conducted 186 375 consultations 
during the 26-week surveillance period, of which 
1176 (six per 1000 consultations) were for patients 
with ILI. Consultations for ILI were significantly higher 
for metropolitan GPs compared to rural GPs (seven and 
five per 1000 consultations, respectively; P < 0.001). 
During the same period, 948 cases of ILI were 
diagnosed from 76 267 MMDS consultations (12 per 
Figure 1. General Practice Sentinel Surveillance (GPSS) and Melbourne Medical Deputising Service (MMDS) 
influenza-like illness (ILI) consultation rates, Victoria, Australia, 2003 to 2012
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Table 1. Laboratory-confirmed influenza cases* by surveillance source, age group and type/subtype, Victoria, 
Australia, 2012
Source Age group (years)
A/H1 A/H3 A (not subtyped) B
n % n % n % n %
Notifi ed cases 0–4 18 27 13 8 471 12 48 6
5–14 7 10 11 7 400 10 182 25
15–29 14 21 21 13 543 13 149 20
30–49 11 16 35 22 1117 28 194 26
50–64 10 15 25 16 580 14 74 10
≥ 65 7 10 51 33 940 23 94 13
Not reported – – – – 4 – 4 –
Total 67 100 156 100 4055 100 745 100
GPSS 0–4 3 13 23 11 2 22 2 5
5–14 2 8 32 16 1 11 9 24
15–29 5 21 28 14 3 33 11 29
30–49 9 38 69 34 3 33 13 34
50–64 5 21 35 17 0 0 2 5
≥ 65 0 0 18 9 0 0 1 3
Total 24 100 205 100 9 100 38 100
FluCAN 0–4 – – – – 22 6 5 10
5–14 – – – – 7 2 4 8
15–29 – – – – 28 8 9 18
30–49 – – – – 59 17 13 26
50–64 – – – – 54 16 4 8
≥ 65 – – – – 169 50 15 30
Total – – – – 339 100 50 100
Notified cases – cases notified to Department of Health; GPSS – General Practice Sentinel Surveillance; FluCAN – Influenza Complications 
Alert Network.
* Excluding 29 notified cases of type A and B coinfection and 10 cases of type C (six notified cases and four from GPSS).
Figure 2. Number of laboratory-confirmed influenza cases and influenza-like illness consultation rates by 
surveillance source, Victoria, Australia, 30 April to 28 October 2012
Notified cases – cases notified to Department of Health; GPSS – General Practice Sentinel Surveillance; FluCAN – Influenza 
Complications Alert Network; ILI – influenza-like illness; MMDS – Melbourne Medical Deputising Service
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aged 65 years or older from FluCAN and notified cases 
(47% and 22%, respectively) but not GPSS (7%). 
However, the rate of notified cases was highest for 
those aged zero to four years and 65 years or older, with 
154 and 137 notified cases per 100 000 population, 
respectively, compared to 61–90 per 100 000 for the 
other age groups.
There was a significant difference in the age 
distribution of notified cases by influenza type B and 
A subtypes (excluding influenza A cases that were not 
subtyped, P < 0.001). A higher proportion of influenza 
A/H1 cases were aged zero to four years, whereas for 
influenza A/H3 cases, a higher proportion were aged 
65 years or older. There was no difference observed 
in GPSS (P = 0.12) (Table 1). In FluCAN, cases of 
influenza type A were significantly older than those with 
type B (P = 0.003).
Vaccination status
Vaccination status was recorded for 688 (97%) of 
709 swabbed GPSS patients of whom 168 (24%) 
reported being vaccinated. FluCAN collected vaccination 
status from cases and influenza-negative controls and 
recorded vaccination status for 772 of 935 (83%) 
patients who had been swabbed, half of whom were 
Of the 1176 ILI cases identified from GPSS, 
709 (60%) were swabbed and 280 (39%) were 
positive for influenza. The proportion of swabbed ILI 
cases positive for influenza ranged from 15%–25% 
until mid-June then quickly rose to 40%–60% until late 
September, and from 35% in 50–64 year-olds to 54% 
among those aged 5–14 years (P = 0.06). Of the 280 
laboratory-confirmed influenza cases from GPSS, 205 
(73%) were A/H3 infections, 24 (9%) were A/H1, 38 
(14%) were type B and four were type C; specimens 
from the remaining nine influenza A cases contained 
insufficient virus for subtyping. Most (71%) of the type B 
cases were detected in August and September (Figure 3). 
The majority of the 389 FluCAN cases (n = 339; 87%) 
were type A but were not subtyped.
Sixteen notified cases were reported to have died 
due to influenza: one due to type B infection and the 
remainder type A, of which three were subtyped as H3. 
Twelve cases were aged 65 years or older, one was aged 
zero to four years, with the remaining three cases aged 
between five and 64 years.
The age group with the highest proportion of 
laboratory-confirmed cases was those aged 30–49 years 
for both notified cases (27%) and GPSS (34%). 
There were also relatively high proportions of cases 
Figure 3.  Number of laboratory-confirmed influenza cases by type/subtype* and surveillance source, Victoria, 
Australia, 30 April to 28 October 2012
Notified cases – cases notified to Department of Health; GPSS – General Practice Sentinel Surveillance 
*  4055 cases of influenza A that were not further subtyped were excluded.
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in the 50–64 year age group and 90% in the 65 years 
or older age group.
Strain characterization and antiviral resistance 
testing
A total of 1293 patient specimens were submitted to 
the WHO Collaborating Centre in 2012. Culture was 
attempted for 1095 of these samples, with 563 (51%) 
yielding an influenza virus isolate: 470 (83%) type A 
viruses, 92 (16%) type B viruses and one type C virus. 
Most of the viruses isolated were A/H3 viruses (n = 437, 
93%) with most of these (82%) being antigenically 
similar to the A/Perth/16/2009 virus used in the 
seasonal influenza vaccine. A/H1 viruses comprised 
just 7% (n = 33), with 29 being antigenically similar 
to the A/California/7/2009 strain used in the vaccine; 
the remaining four were low reactors (haemagglutination 
inhibition titre ≥ 8 fold lower). Among the 92 type B 
viruses isolated, 54 (59%) were antigenically similar to 
the B/Brisbane/60/2008 (Victoria lineage) strain used 
in the vaccine. The remainder included 16 Victoria and 
21 Yamagata lineage viruses.
Neuraminidase inhibition assays indicated that 
none of the 473 viruses tested was resistant to any of 
the antiviral drugs tested.
vaccinated (n = 385; 50%). There was no statistically 
significant difference between the proportion of influenza-
positive and -negative patients with known vaccination 
status in either GPSS (P = 0.89) or FluCAN (P = 0.23). 
For both surveillance data sets the proportion of patients 
vaccinated increased with age (Figure 4). With the 
exception of those aged 65 years or older in GPSS, 
the proportion of influenza-positive patients who were 
vaccinated in adult age groups was lower than the 
proportion of influenza-negative patients who were 
vaccinated in each system.
Comorbidities
Data on comorbidities for which influenza vaccination 
is indicated were  reported for 632 (89%) of the 
709 swabbed patients from GPSS. The presence of 
a comorbid condition was reported for 111 (18%) of 
swabbed patients; there was no difference between 
influenza-positive and influenza-negative patients 
(17% compared with 18%; P = 0.60). However, the 
proportion with a reported comorbidity rose steadily 
with increasing age group from 3% in those aged zero 
to four years to 58% in the 65 years or older age group 
(P < 0.001). In FluCAN patients, the proportion with a 
reported comorbidity rose steadily with increasing age 
group from 31% in those aged zero to four years to 87% 
Figure 4. Proportion of General Practice Sentinel Surveillance (GPSS) and Influenza Complications Alert 
Network (FluCAN) patients vaccinated* by influenza status, age group and surveillance source, 
Victoria, Australia, 2012
* Includes only those patients who were swabbed and tested for influenza.
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caused by A/H3 virus infections across all ages as well 
as increased testing.
The proportion of ILI patients who were swabbed in 
GPSS declined to 60% in 2012 from 71% in both 2010 
and 2011.7,8 As the aim of this component of GPSS is 
to determine what strains are circulating each season, 
demographic and other data are not collected on these 
patients. Therefore further comparison cannot be made, 
neither over the years nor between those that were 
swabbed or not. While providing flexibility to the doctors, 
discretionary swabbing is also a limitation of GPSS as 
factors that may influence a GP to differentially swab one 
patient over another (such as age or vaccination status) 
are unknown.
Vaccination coverage among patients in both GPSS 
and FluCAN systems increased between 2011 and 
2012, possibly due to a shift in age distribution to older 
patients in 2012.6,18 Higher vaccination coverage in 
FluCAN patients compared to GPSS in both years may be 
due to the older age distribution and higher prevalence of 
comorbid conditions indicated for influenza vaccination 
(groups for which influenza vaccine is provided free 
through the National Immunization Programme4) of 
those attending hospitals compared to general practice.
Two observations from the surveillance system 
suggest that the 2012 seasonal trivalent influenza 
vaccine (comprised of A/California/7/2009 (H1N1)
pdm09-like virus, an A/Perth/16/2009 (H3N2)-like 
virus and a B/Brisbane/60/2008-like virus)19 may have 
been moderately effective. First, the results of strain 
typing suggested a good antigenic match of vaccine 
strains – particularly the A/H1 and A/H3 subtypes – to 
a high proportion of Victorian isolates for which strain 
characterization testing was undertaken. Second, a 
higher proportion of swabbed patients in nearly all adult 
age groups of GPSS and FluCAN who were negative for 
influenza were vaccinated compared to those who tested 
positive. However, these findings should be interpreted 
with caution. We have previously demonstrated with 
Victorian data that an apparent good match of vaccine 
to circulating strains does not necessarily correlate with 
greater vaccine effectiveness.20 It has been suggested 
that antibody immunity measured by haemagglutination 
inhibition assay may not be an optimal correlate of 
protection against clinical infection because it may not 
always detect drift in the haemagglutinin antigen.21,22 
Also, the relatively few participating institutions and 
DISCUSSION
The magnitude of ILI activity in the 2012 influenza 
season in Victoria, as shown by GPSS and MMDS, was 
slightly higher than 2010 and 2011 but broadly average 
compared to the previous 10 years. Although the 
proportion of ILI patients identified by MMDS was higher 
than GPSS, both were consistent with trends observed 
in previous years. The number of laboratory-confirmed 
influenza cases from GPSS was also comparable to 
2010 and 2011.7,8 The number of patients reported 
through FluCAN in 2012 was considerably higher than 
the 146 cases reported in 2011 (the first year that all 
four hospitals participated in FluCAN).9 Notified cases 
of laboratory-confirmed influenza increased by 68% in 
2012 compared to 2011 and was also much higher than 
the 1914 notified cases in 2010.7,8 This increase was 
disproportionate compared with that of the other data 
sources in the Victorian surveillance system; therefore 
we believe the increase in notified cases reflects an 
increase in testing rather than a dramatic increase in 
disease.10
Type A influenza peaked during July and August, 
with a much smaller peak of type B in September. 
Subtyping of viruses from GPSS and a subset of notified 
cases indicated the 2012 season was dominated 
by influenza A/H3, continuing the trend of seasonal 
dominance of A/H3 away from the emergence and 
almost exclusive predominance of influenza A(H1N1)
pdm09 in 2009.11 A season in which H3 is the dominant 
subtype followed by a smaller type B increase is a well-
established pattern of influenza epidemics during the 
winter months of temperate zones,12 as in Victoria in 
2007,13 New Zealand in 2012,14 the United States of 
America15 and Canada16 during the 2012/13 northern 
hemisphere influenza season.
Although the type A influenza reported through 
FluCAN were not further characterized, it is likely that 
a substantial proportion were A/H3 infections, given 
that a high proportion of FluCAN cases were aged 
65 years or older and that many cases in this age group 
among notified cases were A/H3. A higher median age 
of A/H3 cases compared to seasonal A/H1 and type B 
cases has recently been observed in Victoria.17 However, 
the increase of H3 in older cases only partially explains 
the increase in all notified cases; similar proportional 
increases were observed across all age groups, possibly 
arising from increased presentation of more severe cases 
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Laboratory testing was conducted by the Viral 
Identification Laboratory at VIDRL and public health 
follow-up was undertaken by the Investigation and 
Response Section, Communicable Disease Prevention 
and Control Unit in the Department of Health. Staff of the 
WHO Collaborating Centre for Reference and Research 
on Influenza provided influenza strain identification data 
to the weekly VIDRL surveillance report.
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limited number of specimens forwarded for strain 
characterization may not necessarily be representative of 
all virus/es circulating in the community. The calculation 
of influenza vaccine effectiveness from surveillance 
data requires application of a more systematic 
methodology,18,23 which will be reported separately.
The inclusion of hospitalized cases from FluCAN 
augmented the Victorian influenza surveillance system 
in 2012 by including cases at the severe end of the 
clinical spectrum. However, while FluCAN cases were 
reported independently, they were also included in the 
notified cases data set. While community surveillance 
suggested a relatively benign influenza season, hospital 
data indicated an increase in severe disease among 
older people, presumably associated with A/H3. This 
demonstrates the importance of using a range of 
surveillance data sources. Efforts are continuing to 
improve the quality and breadth of integrated influenza 
surveillance in Victoria by subtyping a higher proportion 
of type A influenza infections (especially those identified 
through FluCAN) and examining the feasibility of 
establishing ILI and influenza surveillance in hospital 
emergency departments.
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